Latest news with #Becton
Business Upturn
13-06-2025
- Business
- Business Upturn
Flow Cytometry Market Hits US$10.3B by 2032: Why Every Lab Needs a FACS Flow Cytometer?
Delray Beach, FL, June 13, 2025 (GLOBE NEWSWIRE) — Ever wondered how scientists peek inside our cells, analyzing their secrets to diagnose diseases or develop life-saving therapies? It's all thanks to flow cytometry, a dynamic field transforming healthcare and research. And at its core, the remarkable FACS flow cytometer market leads the charge, offering unparalleled precision in analyzing and sorting cells. Imagine a sophisticated, high-speed sorting machine for microscopic cells. That's essentially what a flow cytometer machine does, and the FACS flow cytometer excels, providing meticulous insights into everything from cell cycle flow to identifying disease-causing biomarkers. Download PDF Brochure: This market is exploding, projected to jump from US$5.1 billion in 2024 to US$10.3 billion by 2032, growing at a robust 9.2% CAGR. What's fueling this surge? Rapid technological advancements (especially in FACS flow cytometer systems), increasing adoption in clinical diagnostics, rising chronic disease rates, booming biopharmaceutical R&D, and the urgent demand for precision medicine. Even AI and machine learning are boosting data analysis, accelerating this growth. Why the Buzz? Opportunities & Challenges in Flow Cytometry The global flow cytometry market offers exciting opportunities, but it's not without hurdles: Drivers: Innovation Pushes Boundaries The market thrives on new, advanced flow cytometry products and flow cytometer machines. Manufacturers are focused on creating instruments that are powerful, user-friendly, and incredibly fast. A cutting-edge FACS flow cytometer can analyze and sort thousands of cells per second with unmatched accuracy. Recent innovations like multiplexing, higher throughput systems, and smarter data analysis software are making these tools indispensable. Case in point: In April 2024, Becton, Dickinson and Company launched the BD FACSDiscover S8 Cell Sorter. This advanced spectral cell sorter, a prime FACS flow cytometer, combines real-time imaging with spectral analysis—a game-changer for detailed cellular purification. Restraints: The Cost Barrier Despite the benefits, high costs pose a challenge. Labs often require many flow cytometry instruments, leading to significant capital and maintenance expenses. For academic & research laboratories with restricted budgets, affording a high-end FACS flow cytometer can be tough. A single flow cytometer machine can cost over USD 500,000, and FACS flow cytometer-based cell sorters are typically pricier than cell analyzers due to their precision. This cost can slow adoption, especially in emerging countries. Opportunities: Expanding Clinical Horizons Increased use in clinical applications and infectious disease diagnostics is a massive opportunity. A cell cytometer, particularly a precise FACS flow cytometer, is invaluable for disease diagnosis, prognosis, and monitoring. In hematology, it's key for leukemia and lymphoma diagnosis, identifying rare cancer cells. In immunology, it helps diagnose immunodeficiencies and autoimmune disorders. Example: In March 2024, Beckman Coulter's DxFLEX Clinical Flow Cytometer received USFDA clearance, validated for 10-color immunophenotyping for leukemia and lymphoma—a clear win for clinical FACS flow cytometer applications. Challenges: Reagent Complexity Complexities related to reagent development present a notable challenge. These reagents (like fluorescently labeled antibodies and dyes) are vital for any flow cytometer machine, including FACS flow cytometer systems. Creating high-quality, specific, and stable reagents is time-consuming and resource-intensive, requiring extensive testing to ensure accurate, reproducible results across diverse applications. Request Sample Pages: Who's Driving Growth? Market Segments & Global Leaders Reagents & Consumables: This segment dominated the flow cytometry market in 2023 , essential for any flow cytometer machine , especially advanced FACS flow cytometer systems. This segment dominated the , essential for any , especially advanced systems. Academic & Research Institutes: Poised for substantial growth, driven by increased investment in clinical trials, drug development, and a demand for high-throughput FACS flow cytometer capabilities. Poised for substantial growth, driven by increased investment in clinical trials, drug development, and a demand for high-throughput capabilities. North America: Led the global flow cytometry market in 2023 due to robust healthcare infrastructure, significant investment in research and development, and high adoption of advanced flow cytometry technologies. The Asia Pacific region is expected to show significant growth. Key market players like Becton, Dickinson and Company (US), Danaher Corporation (US), and Thermo Fisher Scientific Inc. (US) are continuously innovating, often focusing on new FACS flow cytometer models to strengthen their market position. Recent Developments: From Agilent's NovoCyte Opteon Spectral Flow Cytometer (May 2024) to Sony's FP7000 spectral cell sorter (October 2023) and BD's groundbreaking FACSDiscover S8 Cell Sorter (March 2023), these innovations highlight the rapid evolution of FACS flow cytometer technology. FAQs Shaping Industry Conversations: 1. What is the core purpose of a Flow Cytometer machine? A flow cytometer machine rapidly analyzes and sorts microscopic cells in fluid, using lasers to gather data on cell size, granularity, and specific markers via scattered light and fluorescence. Essential for both fundamental research and precise disease diagnosis. 2. How does a FACS Flow Cytometer elevate cellular analysis? A FACS flow cytometer goes beyond analysis. As an advanced cell cytometer, it physically separates and collects specific cell populations based on their characteristics. This allows for high-purity isolation of rare cells, crucial for in-depth research and therapeutic development. 3. Why is the global flow cytometry market experiencing such explosive growth? The global flow cytometry market is booming, projected to reach US$10.3 billion by 2032, driven by tech advancements (e.g., spectral analysis in FACS flow cytometer), rising adoption in clinical diagnostics, increasing chronic disease prevalence, and surging biopharmaceutical R&D. AI and machine learning further accelerate this expansion. 4. What are the key hurdles in adopting flow cytometry instruments? The main challenge is the high cost of instruments, often exceeding USD 500,000, especially for advanced FACS flow cytometer models. Complexities in reagent development also add to the operational cost, limiting adoption for smaller academic & research laboratories with restricted budgets. 5. How critical is flow cytometry in understanding cell cycle flow and diagnosing blood cancers? Flow cytometry is vital for studying cell cycle flow by analyzing cellular DNA content. Clinically, a FACS flow cytometer is indispensable for diagnosing hematological malignancies like leukemia and lymphoma, by precisely identifying and characterizing abnormal immune cell populations based on unique surface markers. For more information, Inquire Now! Related Reports: Single Cell Analysis Market Cell Based Assays Market Esoteric Testing Market Research Antibodies Market Cell Analysis Market Get access to the latest updates on Top Companies in Flow Cytometry and Flow Cytometry Market Size Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
Malaysian Reserve
28-05-2025
- Business
- Malaysian Reserve
BD to Initiate Real-World Patient Data Registry for the Rotarex™ Atherectomy System in Treatment of Peripheral Artery Disease
FRANKLIN LAKES, N.J., May 28, 2025 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced plans to initiate a patient data registry for the Rotarex™ Atherectomy System to measure real-world outcomes for patients with peripheral artery disease (PAD). Known as 'XTRACT,' this prospective, multi-center, single-arm, post-market registry study will assess the clinical performance of the Rotarex™ Atherectomy System in the treatment of U.S. patients with PAD lesions. The XTRACT Registry is being led in partnership with Co-Principal Investigators, Dr. Prakash Krishnan, an interventional cardiologist, and Dr. Todd Berland, a vascular surgeon. The registry will enroll up to 600 patients at approximately 100 clinical sites across the United States, with the first patient enrollment expected later this year. Clinical follow-up evaluations will occur after 30 days, 6 months and 12 months post-procedure to assess safety and effectiveness of outcomes. 'This registry will provide valuable data to support clinical decision-making and enhance patient outcomes in the management of PAD,' said Dr. Krishnan. 'The Rotarex™ System has been extensively studied internationally, and we are excited to further evaluate its adaptability in treating a wide range of PAD lesions within the U.S. patient population.' The Rotarex™ Atherectomy System is a minimally invasive solution designed to efficiently remove both plaque and thrombus in peripheral arteries. Offering dual indications as both an atherectomy and thrombectomy device, the Rotarex™ Atherectomy System is a proven tool for treating PAD. 'The XTRACT Registry is the first comprehensive registry aimed at providing key insights into the real-world applications of the Rotarex™ System,' said Rima Alameddine, worldwide president of BD Interventional-Peripheral Intervention. 'This study underscores our unwavering commitment to optimizing treatment strategies in partnership with leading physicians to improve patient care.' PAD is a potentially debilitating disease that is estimated to affect more than 21 million Americans and more than 200 million people worldwide and can lead to increased risk of cardiovascular complications and lower limb amputation.1,2 The XTRACT Registry underscores BD's ongoing commitment to innovative technological development and evidence-based research that support physicians and improve patient outcomes. About BDBD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit or connect with us on LinkedIn at X (formerly Twitter) @BDandCo or Instagram @becton_dickinson. Contacts: Media: Investors: Troy Kirkpatrick Adam Reiffe BD Public Relations BD Investor Relations 858.617.2361 201.847.6927 1 Yost, Mary. The Current U.S. Prevalence of Peripheral Arterial Disease. Vascular Disease Management. 2023;20(4):E67-E732 Allison MA, Armstrong DG, Goodney PP, et al. Health Disparities in Peripheral Artery Disease: A Scientific Statement From the American Heart Association. Circulation. 2023;148:286-296. doi:10.1161/CIR.0000000000001153
Yahoo
28-05-2025
- Business
- Yahoo
BD to Initiate Real-World Patient Data Registry for the Rotarex™ Atherectomy System in Treatment of Peripheral Artery Disease
FRANKLIN LAKES, N.J., May 28, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced plans to initiate a patient data registry for the Rotarex™ Atherectomy System to measure real-world outcomes for patients with peripheral artery disease (PAD). Known as "XTRACT," this prospective, multi-center, single-arm, post-market registry study will assess the clinical performance of the Rotarex™ Atherectomy System in the treatment of U.S. patients with PAD lesions. The XTRACT Registry is being led in partnership with Co-Principal Investigators, Dr. Prakash Krishnan, an interventional cardiologist, and Dr. Todd Berland, a vascular surgeon. The registry will enroll up to 600 patients at approximately 100 clinical sites across the United States, with the first patient enrollment expected later this year. Clinical follow-up evaluations will occur after 30 days, 6 months and 12 months post-procedure to assess safety and effectiveness of outcomes. "This registry will provide valuable data to support clinical decision-making and enhance patient outcomes in the management of PAD," said Dr. Krishnan. "The Rotarex™ System has been extensively studied internationally, and we are excited to further evaluate its adaptability in treating a wide range of PAD lesions within the U.S. patient population." The Rotarex™ Atherectomy System is a minimally invasive solution designed to efficiently remove both plaque and thrombus in peripheral arteries. Offering dual indications as both an atherectomy and thrombectomy device, the Rotarex™ Atherectomy System is a proven tool for treating PAD. "The XTRACT Registry is the first comprehensive registry aimed at providing key insights into the real-world applications of the Rotarex™ System," said Rima Alameddine, worldwide president of BD Interventional-Peripheral Intervention. "This study underscores our unwavering commitment to optimizing treatment strategies in partnership with leading physicians to improve patient care." PAD is a potentially debilitating disease that is estimated to affect more than 21 million Americans and more than 200 million people worldwide and can lead to increased risk of cardiovascular complications and lower limb amputation.1,2 The XTRACT Registry underscores BD's ongoing commitment to innovative technological development and evidence-based research that support physicians and improve patient outcomes. About BDBD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit or connect with us on LinkedIn at X (formerly Twitter) @BDandCo or Instagram @becton_dickinson. Contacts: Media: Investors: Troy Kirkpatrick Adam Reiffe BD Public Relations BD Investor Relations 858.617.2361 201.847.6927 1 Yost, Mary. The Current U.S. Prevalence of Peripheral Arterial Disease. Vascular Disease Management. 2023;20(4):E67-E732 Allison MA, Armstrong DG, Goodney PP, et al. Health Disparities in Peripheral Artery Disease: A Scientific Statement From the American Heart Association. Circulation. 2023;148:286-296. doi:10.1161/CIR.0000000000001153 View original content to download multimedia: SOURCE BD (Becton, Dickinson and Company) Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
27-05-2025
- Business
- Yahoo
BD to Present at Goldman Sachs 46th Annual Global Healthcare Conference
FRANKLIN LAKES, N.J., May 27, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present at the Goldman Sachs 46th Annual Global Healthcare Conference on Monday, June 9, 2025 at 2:00 pm Eastern Time. The live webcast of BD's presentation can be accessed from the BD investor relations website, A replay of the event will be available on the same webpage following its conclusion. About BDBD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit or connect with us on LinkedIn at X (formerly Twitter) @BDandCo or Instagram @becton_dickinson. Contacts:Media: Investors: Troy Kirkpatrick Adam Reiffe VP, Public RelationsSr. Director, Investor Relations 858.617.2361201.847.6927 View original content: SOURCE BD (Becton, Dickinson and Company) Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Fashion Value Chain
27-05-2025
- Health
- Fashion Value Chain
BD Safe Emergency Seminar Launched to Provide Rich Knowledge Sharing Platform for Emergency Department Doctors
To raise awareness and foster discussions on the safety of healthcare workers (HCWs) in emergency departments, BD (Becton, Dickinson and Company) has recently launched the 'Safe Emergency Seminar' series across locations in India. BD safe emergancy seminar being conducted across India The emergency departments in hospitals typically demand high efficiency, which, in turn, increases the risk of blood exposure, blood splashes, and needlestick injuries (NSIs). Such incidents can expose healthcare workers to serious diseases like Hepatitis A, Hepatitis B, and HIV. The BD Safe Emergency seminar aims to provide a platform to bring together doctors from Emergency departments from across hospitals in each city to convene upon and discuss best practices for healthcare worker safety in high- efficiency demanding environment. Commenting on the Safe Emergency seminar series, Atul Grover, Managing Director, BD India/South Asia said, 'Our Safe Emergency seminar is a concerted effort to bring the spotlight on healthcare worker safety especially in dynamic and high efficiency demanding environments. We are committed to providing a platform for creating awareness and sharing best practices on this pertinent topic. This initiative is part of BDs broader commitment to ensuring the well-being of healthcare professionals and enhancing patient outcomes in alignment with our purpose of advancing the world of health.' The Safe Emergency seminars organized across cities featured in-depth scientific discussions on the burden of blood exposure, sharp safety, and vascular access in emergency departments. Experts from leading city hospitals shared valuable insights and data on needle stick injuries (NSI), blood exposure and splash thereby reinforcing the need for stringent safety protocols to protect healthcare workers. The discussions were followed by case studies that illustrated real-world scenarios and the effectiveness of various safety measures. About BD-India BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics, and the delivery of care. BD helps customers enhance outcomes, lower costs, increase efficiencies, improve safety, and expand access to health care. Disclaimer The image used in this press release is a stock photo and is for illustrative purpose only. The person(s) depicted herein are models. All content herein is protected by copyright, trademark and other intellectual property rights, as applicable, owned by or licensed to Becton Dickinson or its affiliates unless otherwise indicated.
